Evidence map›Paper›PMID 38982387›Full record

ArticleBMC cancer2024

Correction: the TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain.

R Vera, N Castro, I Labiano, A Lecumberri, A E Huerta, H Arasanz, I Caseda, F Ruiz-Pace, C Viaplana, V Arrazubi and 15 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

R VeraOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
N CastroOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
I LabianoOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
A LecumberriOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
A E HuertaOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
H ArasanzOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
I CasedaOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
F Ruiz-PaceOncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
C ViaplanaOncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
V ArrazubiOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
I Hernandez-GarciaOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
E MataOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
D GomezOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
S LagunaDepartment of Medical Oncology, Hospital Universitario de Navarra (HUN), Pamplona, Spain.
J SuarezDepartment of Surgery, Hospital Universitario de Navarra (HUN), Pamplona, Spain.
I Fernandez-De-Los-ReyesDepartment of Pathology, Hospital Universitario de Navarra (HUN), Pamplona, Spain.
M RullanDepartment of Gastroenterology and Hepatology, Hospital Universitario de Navarra (HUN), Pamplona, Spain.
F EstremeraDepartment of Gastroenterology and Hepatology, Hospital Universitario de Navarra (HUN), Pamplona, Spain.
V AlonsoDepartment of Medical Oncology, Hospital Universitario Miguel Servet, IISA, Zaragoza, Spain.
R Pazo-CidDepartment of Medical Oncology, Hospital Universitario Miguel Servet, IISA, Zaragoza, Spain.
A Gil-NegreteDepartment of Medical Oncology, Hospital Universitario Donostia, San Sebastian, Spain.
A LafuenteDepartment of Medical Oncology, Hospital San Pedro, Logroño, Spain.
A Martin-CarniceroDepartment of Medical Oncology, Hospital San Pedro, Logroño, Spain.
R DienstmannOncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
M AlsinaOncobiona Group, Navarrabiomed-Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain. maria.alsina.maqueda@navarra.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38982387
PMCPMC11234692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.